Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2019

View Archived Issues

BioInvent discloses a program to target TNFR2 for the treatment of solid tumors

VLP Therapeutics initiates phase I study of VLPM-01 vaccine

Lead Pharma initiates phase I study of SAR-441169

Insight into the metabolic-epigenetic interplay of fumaric acid esters in brain-homing T cells in MS

Ahammune Biosciences discloses compounds for celiac disease

NLRP3 inflammasome inhibitors synthesized at Cadila Healthcare

Kappa-opioid receptor agonists patented by University of Tsukuba, Nippon Chemiphar

Shanghai Meizer Pharmaceuticals identifies new Bruton tyrosine kinase inhibitors

Orion, Gedeon Richter describe D-amino-acid oxidase inhibitors

Toray Industries discovers nuclear receptor ROR-gamma antagonists

Gene editing success in blood stem cells

Phase II safety data for nivolumab in combination with ipilimumab in metastatic uveal melanoma

BKM-1972 inhibits intraosseous growth of chemosensitive and chemoresistant prostate cancer

Aberrant SATB2 expression as a novel biomarker of IBD-associated colorectal neoplasia

Data for [177Lu]PP-F11N presented for medullary thyroid carcinoma

TIA1 shows a physiological and partly sex-dependent role in avoidance behavior and fear memory

Blood needs Prozac, too

Autosomal myopathy protein compensates for X-linked form

Oncolytic reovirus is active against castration-resistant prostate cancer

European Commission approves Forxiga for type 1 diabetes

FDA issues second complete response letter for Recro's intravenous meloxicam

UGRP1 for differential diagnosis of Hashimoto's hyperthyroidism among patients with Graves' disease

Ovoca reports phase III data on Libicore for women with hypoactive sexual desire disorder

Phase II trial of SFX-01 in metastatic breast cancer meets primary endpoints

Arvinas initiates phase I study of ARV-110 in metastatic castration-resistant prostate cancer

Proteostasis reports data set on CFTR modulator triple combination therapy

FDA issues complete response letter for Zynquista for type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...